Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 10441-10450 Newer>

BusinessWeek November 7, 2005 Robert Barker	Lend An Ear To Plantronics Getting consumers to see its in-your-ear electronics as fashion objects is a major challenge now facing Plantronics.
BusinessWeek November 7, 2005 Gene G. Marcial	Writing On USG's Wall? Is time running out for gypsum wallboard maker USG?
BusinessWeek November 7, 2005 Gene G. Marcial	Hungry Banks Are Eyeing Advanta After Bank of America acquired credit-card lender MBNA in mid-July, other banks started looking for acquisitions.
BusinessWeek November 7, 2005 Gene G. Marcial	Southwest Airlines Wings North Airlines have been out of favor on Wall Street.
The Motley Fool October 28, 2005 Stephen D. Simpson	Will ABB Put It Together? With new management in place, is it possible that this Swiss power and automation conglomerate could be a real turnaround success story?
The Motley Fool October 28, 2005 Bobby Shethia	Booming Back From the Brink After three straight years of losses, Tweeter is ready for a turnaround. And it looks like a bargain at 17% of sales.
The Motley Fool October 28, 2005 W.D. Crotty	Ugg on Its Face Deckers' current sales concentration in Ugg makes it appear as though the company's fortune should move in whichever direction Ugg moves. Hurting the stock -- besides two brokerage downgrades -- was the lowering of fiscal 2005 earnings and a lackluster 2006 projection.
The Motley Fool October 28, 2005 Jeff Hwang	Overstock's Ugly Q3 Things aren't looking good at the online discount retailer, but maybe their new team can help put things back on track. Investors, stay tuned.
The Motley Fool October 28, 2005 Nathan Parmelee	BJ's Cooks Up Tasty Results BJ's Restaurants continues its amazing performance. The company will offer an intriguing investment opportunity sooner or later, investors just need to be patient.
The Motley Fool October 28, 2005 Stephen D. Simpson	Bristol-Myers' Bad Mojo The possible loss of the experimental diabetes drug Pargluva is a blow to this pharmaceutical that's already hurting for growth. If you're expecting a near-term bang for your investment buck, this might not be the best destination.
<Older 10441-10450 Newer> Return to current articles.